ELVN FY 2023 Earnings — Enliven Therapeutics, Inc. Revenue & Financial Results | Market Cap Arena

ELVNEnliven Therapeutics, Inc.

$2B

FY 2023 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$0

Gross Profit

$0

Operating Income

-$84M

Net Income

-$72M

EPS (Diluted)

$-2.01

Cash Flow

Operating Cash Flow

-$61M

Free Cash Flow

-$61M

Stock-Based Comp.

$13M

Balance Sheet

Total Assets

$272M

Total Liabilities

$26M

Stockholders' Equity

$246M

Cash & Equivalents

$100M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$0	$0	—
Gross Profit	$0	$0	—
Operating Income	-$84M	-$39M	-115.3%
Net Income	-$72M	-$38M	-90.1%